A securities class action has been filed in the USDC – S.D.CA. against Dexcom, Inc. (DXCM) (“DexCom” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, both dates inclusive (the “Class Period”).
Dexcom develops, manufactures, and markets continuous glucose monitors (“CGMs”). In early 2023, Dexcom launched the latest generation of its CGM, which it called the G7.
The complaint alleges throughout the Class Period, Defendants failed to disclose that:
(1) DexCom had made material design changes to the G6 and G7 unauthorized by the U.S. Food and Drug Administration (the “FDA”);
(2) these design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings;
(3) these issues subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action as well as significant legal and reputational harm;
(4) based on the foregoing, the Company’s CGM sales were negatively impacted; and
(5) as a result, Defendants’ public statements about the reliability, accuracy, safety, and functionality of their CGMs as well as their financial forecasts were materially false and/or misleading at all relevant times, thereby harming investors.
On September 18, 2025, DexCom’s stock price fell $8.99 per share, or 11.8 percent, over the following two trading sessions to close at $67.45 per share on September 19, 2025.
If you purchased DexCom securities during the Class Period, and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.